Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 5/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL28133460 | 0.97 | OAT (0.35) | OATDPP7DPP8DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL3154232 | 0.97 | OAT (0.35) | OATDPP7DPP8DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL3708706 | 0.95 | OAT (0.34) | OATDPP7DPP8DPP4GABRR1 | |
| Trifluoroacetic Acid SCHEMBL3043598 | 0.92 | MMP8 (0.33) | OATDPP7DPP8DPP4DPP9 | |
| Cyclohexylamine SCHEMBL1787821 | 0.90 | ALDH1A1 (0.36) | ALDH1A1 | |
| Cycloheptanamine SCHEMBL27746259 | 0.90 | ALDH1A1 (0.36) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4543549 | 0.88 | EPHX2 (0.33) | OAT | |
| Trifluoroacetic Acid SCHEMBL4269674 | 0.88 | EPHX2 (0.33) | OAT | |
| Trifluoroacetic Acid SCHEMBL31525039 | 0.86 | GABRA5 (0.43) | GABRR1HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL28212086 | 0.86 | GABRA5 (0.43) | GABRR1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105121429-B | Complement pathway modulators and uses thereof | 诺华股份有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-8304434-B2 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-101484420-A | Indoles as 5-HT 6 modulators | BIOVITRUM AB PUBL (SE) | 2009-07-15 | — | — | CN | disclosed |
| CN-101282938-A | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-1832922-A | Sulfonyl-substituted N- (biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO INC (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1649870-A | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | TRPV1, TRPA1, CACNA1D | OAT 4013/4885DPP7 650/4885DPP8 760/4885 |
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | OAT 4013/4885DPP7 650/4885DPP8 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.